ACTRN12624000079549尚未招募Unknown
PhaRmacogEnomiC medIcines optimiSatIon for peOple with caNcer – a multicentre teletrial enabled Interrupted Time Series trial (PRECISION-ITS): Medication safety outcomes in the Pharmacogenomics primary study and discovery program
Peter MacCallum Cancer Centre0 个研究点目标入组 1,470 人开始时间: 2024年1月30日最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 发起方
- 入组人数
- 1,470
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Non-randomised trial
- 主要目的
- Treatment
- 盲法
- Open (masking not used)
入排标准
- 年龄范围
- 18 Years 至 o limit（—）
- 性别
- All
入选标准
- •Inclusion Criteria for Patients not receiving 5-FU therapeutic drug monitoring (TDM):
- •1.Aged 18 years or older
- •2.Meets at least one criterion related to cancer diagnosis and treamtent:
- •2.1 UGI/LGI cancer commencing first-line systemic anticancer therapy with first exposure to 5-FU or , capecitabine, or systemic anticancer treatment with first exposure to irinotecan (utilised first or subsequent line) for any stage disease with curative or palliative intent (concurrent radiotherapy and other anticancer therapies permitted).
- •2.2 Breast cancer commencing any CDK4/6 inhibitor, capecitabine, or Sacituzumab govitecan in any line of therapy for any stage disease, with curative or palliative intent (concurrent hormone therapies and other anticancer therapies permitted).
- •2.3 Head and neck cancer commencing curative intent chemo-radiotherapy with high dose cisplatin (70mg/m2 or higher planned dose), with or without immunotherapy.
- •2.4 HL commencing treatment with ABVD-like or escalated BEACOPP-like pathways.
- •2.5 NHL commencing treatment with HyperCVAD, CODOX-M, or treatment containing high-dose methotrexate
- •2.6 CUP receiving treatment for presumed diagnosis of an included cancer and meeting treatment requirements specified for included cancers (2.1 to 2.5)
- •3.Diagnostic workup and treatment plan to be undertaken at participating trial site
- •4.Patient has capacity to provide consent using the ethics approved PICF, and has provided written informed consent
- •5.Patient and/or carer can complete patient surveys
- •6.Study enrolment limit has not been reached
- •Patients with metastatic/unresectable colorectal cancer receiving 5-FU TDM will also be included in the primary PGx study.
- •Inclusion Criteria for patients participating in 5-FU TDM:
- •1. Aged 18 years or older
- •2. Metastatic or unresectable colorectal cancer commencing first-line 5-FU based systemic anticancertherapy or 5-FU based systemic anticancer therapy with first exposure to irinotecan (utilised first or subsequent line); prior treatment for early stage disease permitted.
- •3. Diagnostic work-up and treatment planned to be undertaken at participating trial site.
- •4. Patient has capacity to provide consent using the ethics approved PICF, and has provided writteninformed consent.
- •5. Patient and/or carer can complete patient surveys
- •6. Study enrolment limit has not been reached
排除标准
- •Exclusion Criteria for Patients not receiving 5-FU TDM:
- •1.Commenced systemic anticancer therapy.
- •2.Referral to participating trial site for second opinion only, with no intent for treatment at the participating site
- •3.Patients receiving a PGx drug of interest (Appendix 1) as an investigational medicinal product in another interventional clinical drug trial that prohibits concurrent enrolment (as part of eligibility criteria or at PI’s discretion) or that represents an unreasonable burden of patient participation at the discretion of the patient or investigator.
- •4.Diagnosis of neuroendocrine cancer (due to differences in treatment pathways and routine follow-up schedules).
- •5.Patients receiving HIPEC (due to differences in treatment pathways and routine follow-up schedules).
- •6.Does not meet inclusion criteria
- •The same exclusion criteria apply for patients receiving 5-FU TDM.
- •Exclusion Criteria for patients receiving 5-FU TDM:
- •1. Commenced systemic anticancer therapy.
- •2. Referral to participating trial site for second opinion only, with no intent for treatment at the participating site.
- •3. Patients receiving a pharmacogenomics drug of interest (Appendix 1) as an investigational medicinal product in another interventional clinical drug trial that prohibits concurrent enrolment (as part of eligibility or PI’s discretion), or that represents an unreasonable burden of patient participation at the discretion of the patient or investigator.
- •4. Diagnosis of neuroendocrine cancer (due to diff erences in treatment pathways and routine follow-upschedules).
- •5. Patient is receiving HIPEC (due to differences in treatment pathways and routine follow-up schedules).
- •6. Does not meet inclusion criteria
研究者
相似试验
尚未招募
不适用
PhaRmacogEnomiC medIcines optimiSatIon for peOple with caNcer – a multicentre teletrial enabled Interrupted Time Series trial (PRECISION-ITS): A nested cohort substudy evaluating the safety & efficacy of 5-Fluorouracil Therapeutic Drug Monitoring in patients with metastatic/unresectable colorectal cancer.ACTRN12624000078550Peter MacCallum Cancer Centre200
尚未招募
Unknown
PhaRmacogEnomiC medIcines optimiSatIon for peOple with caNcer – a multicentre teletrial enabled Interrupted Time Series trial (PRECISION-ITS): Pharmacogenomics Education & Implementation Program for PharmacistsCancer and other malignant neoplasmsCancer - Any cancerPublic Health - Health service researchACTRN12624000091505Peter MacCallum Cancer Centre20
已完成
不适用
Pharmacists' review of medicine during admission to hospitalIn-hospital adverse drug eventsOther complications of surgical and medical care, not elsewhere classifiedISRCTN08043800Region Zealand Hospital Pharmacy (Region Sjaelland Sygehusapoteket) (Denmark)648
暂停
不适用
Optimization of the pharmacological component using additive placeboeffects: Is it possible to enhance the psychological component during self-medication by disclosing information about the psychological componentsself-medication: participants using a specific analgesic (ibuprofen, paracetamol, aspirin) for pain relief self-medication: participants using a specific antihistamine (dimetindene, loratadine, cetirizine) for itch reliefDRKS00009506niversitätsklinikum Hamburg-Eppendorf Klinik und Poliklinik für Anästhesiologie108
已完成
不适用
Efficacy of medication optimization protocol for older inpatients: a randomized controlled trialPolypharmacy among older adultsJPRN-UMIN000035265St. Marianna university school of medicine500